Wolfe Catherine, Ionescu Iulia Gabriela, Mayrand Marie-Hélène, Coutlée François, Sauvageau Chantal
Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, Québec, Canada.
Direction des risques biologiques-immunisation, Institut national de santé publique du Québec, Québec, Québec, Canada.
J Infect Dis. 2025 Aug 14;232(2):e203-e212. doi: 10.1093/infdis/jiaf094.
Since 2008, Quebec (Canada) has had a school-based human papillomavirus (HPV) vaccination program achieving >90% coverage (≥ 1 dose) in girls by age 15. In 2018, Quebec was the first jurisdiction to switch to a mixed schedule (nonavalent + bivalent), and as such wanted to evaluate it. However, when devising an evaluation strategy for new vaccine schedules, the presence of herd effect needs to be ascertained. With this in mind, this study aimed to measure HPV prevalence among unvaccinated 16- to 20-year-old sexually active men.
In 2020-2022, men were recruited from schools and online across the province of Quebec. Participants completed an online questionnaire and provided a self-collected penile swab (surface) for HPV detection and genotyping (Anyplex II-HPV28 Detection assay). Risk factors associated with HPV positivity were assessed. Vaccination status (unvaccinated) was verified through the Quebec Vaccination Registry.
Overall, 369 participants provided a sample suitable for HPV testing. HPV prevalence was 18.4% (95% confidence interval [CI], 14.6%-22.8%). Only 2 participants harbored a quadrivalent (4vHPV)-targeted genotype (0.5% [95% CI, .1%-1.9%]), both of whom reported sexual contact with men. In multivariate analysis, age, greater number of lifetime sexual partners, and history of other sexually transmitted infections were independently associated with positivity for at least 1 HPV genotype.
The low 4vHPV-targeted genotype prevalence (<1%) among unvaccinated men of the same age as women vaccinated with 4vHPV suggests a strong herd immunity among young adults in Quebec. Evaluation of schedule changes will have to take this finding into account. Clinical Trials Registration. NCT04297670.
自2008年以来,加拿大魁北克省实施了一项以学校为基础的人乳头瘤病毒(HPV)疫苗接种计划,15岁女孩的接种覆盖率(至少接种1剂)超过90%。2018年,魁北克省是首个改用混合接种方案(九价+二价)的辖区,因此希望对其进行评估。然而,在制定新疫苗接种方案的评估策略时,需要确定群体效应的存在。考虑到这一点,本研究旨在测量16至20岁未接种疫苗的性活跃男性中的HPV流行率。
2020年至2022年期间,在魁北克省全省范围内从学校和网上招募男性。参与者完成一份在线问卷,并提供自行采集的阴茎拭子(表面)用于HPV检测和基因分型(Anyplex II-HPV28检测法)。评估与HPV阳性相关的风险因素。通过魁北克疫苗接种登记处核实接种状态(未接种)。
总体而言,369名参与者提供了适合HPV检测的样本。HPV流行率为18.4%(95%置信区间[CI],14.6%-22.8%)。只有2名参与者携带四价(4vHPV)靶向基因型(0.5%[95%CI,0.1%-1.9%]),两人均报告与男性有性接触。在多变量分析中,年龄、终身性伴侣数量增加以及其他性传播感染史与至少1种HPV基因型阳性独立相关。
与接种4vHPV的女性同龄的未接种疫苗男性中,4vHPV靶向基因型流行率较低(<1%),这表明魁北克省年轻人中存在强大的群体免疫力。接种方案变更的评估必须考虑这一发现。临床试验注册。NCT04297670。